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In the EU, a regulatory framework has been established which deﬁnes general conditions for marketing
authorisation approval of similar biological medicinal products (SBMPs). In addition, the framework
provides product-class speciﬁc recommendations for non-clinical evaluation of speciﬁc SBMPs con-
taining as active substance recombinant somatropin, granulocyte-colony stimulating factor (G-CSF),
erythropoietin, interferon alpha, insulin or low molecular weight heparins.
During the last years, a number of SBMPs have been succesfully licensed in the EU. This article
summarizes the non-clinical evaluations performed for these medicinal products and provides
a comparison with the current requests for non-clinical evaluation as laid down in the respective EU
regulatory guidelines.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
In recent years, pharmaceutical companies have developed so-
called similar biological medicinal products (SBMPs) on basis of
already licensed biological medicinal products, of which patents
have been expired. From a regulatory point of view, a basic
question is whether a generic approach can be used for marketing
approval of these SBMPs. The European Medicines Agency (EMA)
came to the conclusion that, due to the structural complexity of
biological/biotechnology-derived products, the generic approach
is in general not appropriate for this kind of products [1].
According to x 10.4 and to Annex I, Part 2, number 4 of the EU
Directive 2001/83/EC as amended [2], the results of appropriate
pre-clinical tests and/or clinical trials for SBMP have to be provided
in addition to quality data for marketing authorisation applications
in the EU. As laid down in this directive, the general principles to be
applied for marketing authorisation of SBMPs should be addressed
in a guideline, taking into account the characteristics of the con-
cerned biological medicinal products.
2. Regulatory framework for non-clinical evaluation
of SBMP in the EU
On the basis of EU Directive 2001/83/EC, the ‘Guideline on
SBMP’ [1] which was issued by the EMA, states, that for SBMP, the91.
ll rights reserved. The World Healthso-called ‘biosimilar approach, will have to be followed, based on
a comparability exercise’ with a chosen reference biological
medicinal product (RBMP).
Complemented to the general principles deﬁned in the ‘Guideline
on SBMP’, more speciﬁc information concerning the non-clinical
study program recommended for marketing authorisation of SBMPs
in the EU has been provided in a number of guidelines drafted during
the last years by the Biosimilar Medicinal Working Party (BMWP) of
the Committee for Human Medicinal Products (CHMP) of the EMA.
The hierarchical arrangement of these guidelines is shown in Fig. 1:- General issues related to the non-clinical (and clinical)
evaluation of SBMPs containing biotechnology-derived
proteins as active substances have been detailed in
a speciﬁc guideline [3].
- On basis of the general principles laid down in the two
mentioned overarching guidelines [1,3], product-class speciﬁc
guidelines have been issued for SBMPs containing speciﬁc
biotechnology-derived recombinant proteins such as soma-
tropin [4], erythropoietin [5,6], granulocyte-colony stimulating
factor (G-CSF) [7], insulin [8] and interferon alpha [9].
Currently, guidelines for SBMPs containing follicle stimulating
hormone [11], interferon beta [12] and monoclonal antibodies
[13] are drafted by the EMA and will be issued for external
commentation in the near future.
- Recently a product-class speciﬁc GL for low molecular weight
heparins [10], as non-protein substances, has been issued.Organization has granted the Publisher permission for the reproduction of this article.
Fig. 1. Hierarchical arrangement for evaluation of SBMP in the EU.
Table 1
Date of coming into force of product-class speciﬁc EU guidelines for SBMPs and
licensing dates of SBMPs currently approved in the EU.
Active Substance GL Date Licensed SBMP Licening Date
r Somatropin 06/2006  Omnitrope 04/2006
 Valtropin 04/2006




 Filgrastim Hexal, Zarzio 02/2009
 Nivestim 06/2010
r Erythropoietin 07/2006  Abseamed, Binocrit,
Epoietin alfa Hexal
08/2007
 Retacrit, Silapo 12/2007
r Insulin 06/2006 None
r Interferon alfa 04/2009 None
Low MW Heparins 10/2009 None
r ¼ recombinant, GL date ¼ date of coming into force of GL in the EU, Licening
date ¼ date of marketing authorisation approval by EU commission,
MW ¼ molecular weight.
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and their dates of coming into force is presented in Table 1.
According to the existing EU guidelines, the applicant is asked
to provide a ‘comparability exercise’ to demonstrate that the SBMP
is similar to the RBMP in terms of quality, safety and efﬁcacy [3].
Importantly, it may not be necessary to repeat all non-clinical (and
clinical) studies if similarity can be shown from a quality
perspective [14]. In fact, compared with the non-clinical study
program usually requested [15] for the characterization of
a medicinal product containing a new active biotechnology-
derived protein, the non-clinical testing program recommended
in the EU product-class speciﬁc guidelines for SBMPs is substan-
tially reduced, focusing mainly on a demonstration of similar
biological (pharmacodynamic) activity in suitable in vitro and
in vivo test systems and of similar toxicity as evaluated in at least
one repeat dose toxicity study and, if appropriate, a local tolerance
study. Evaluation of safety pharmacology, reproductive toxicity,
genotoxicity and carcinogenicity are not routine requirements for
non-clinical evaluation of SBMPs according to the current EU
guidelines.
In general, for non-clinical evaluation of SBMPs, the studies
should be (i), as part of the ‘comparability exercise’, preferably
comparative in nature, comparing the SBMP and the chosen RBMP
and (ii) designed to detect differences in response between SBMP
and RBMP and not just the response per se.
It should be mentioned that speciﬁc problems may be
encountered in non-clinical evaluation of SBMPs containing
biotechnology-derived proteins. For example, recombinant human
proteins may show species-speciﬁc pharmacodynamic activity and
it may therefore be difﬁcult to identify a relevant species for
pharmacodyamic and toxicological studies. In addition, recombi-
nant human proteins will, as foreign proteins, usually elicit an
antibody response in animal studies and results of long-term
(>2e4 weeks) pharmacodyamic and toxicological studies may
therefore be difﬁcult to interpret due to the formation of SBMP/
antibody complexes [16].3. Similar biological medicinal products currently licensed in
the EU
Table 1 provides an overview of the SBMPs approved until now
in the EU. In the following paragraphs, the recommendations of the
product-class speciﬁc EU biosimilar guidelines and the actual non-
clinical data submitted by the applicants during marketing
authorisation procedures are detailed. An overview of these data is
provided in Table 2.3.1. Somatropin
The principal bioactive human growth hormone is a single chain
non-glycosylated 191 amino acid, 22 kDa polypeptide produced in
the anterior pituitary gland.
Table 2
Non-clinical safety and PK/TK studies (i) requested by product-class speciﬁc EU GLs
for recombinant somatropin, G-CSF and erythropoietins and (ii) submitted for
















rabbit study (NC) None
Valtropin 4-week þ
3-month, rat þ
mice (NC, no AB)




























(þRP þ TK þ AB)
2 rabbit studies (NC)
þ data from RDTS
PK
Retacrit, Silapo 13-week rat þ
13-week dog
(þRP þ TK þ AB)
rabbit study (NC)
þ data from RDTS
None
TK ¼ toxicokinetics, PK ¼ pharmacokinetics, AB ¼ measurement of anti-drug anti-
bodies, RDTS ¼ repeat dose toxicity study, NC ¼ non-comparative study design,
RP ¼ recovery period, Safety PD ¼ safety pharmacology study, Biograstim and
others ¼ Biograstim, Filgrastim ratiopharm, Ratiograstim, Tevagrastim.
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identical amino acid sequence and is produced by recombinant
technology using E. coli, mammalian cells or yeast cells as an
expression system.
Somatropin has potent anabolic, lipolytic and anti-insulin effects
(acute insulin-like effect). The effects of somatropin are mediated
both directly (e.g. on adipocytes and hepatocytes) and indirectly, via
stimulation of insulin-like growth factors (principally IGF-1).
Somatropin-containingmedicinal products are currently licensed
for normalising or improving linear growth and/or body composition
in growth hormone-deﬁcient and certain non-growth hormone-
deﬁcient states. The same receptors are thought to be involved in all
currently approved therapeutic indications of recombinant human
somatropins. Somatropin is administered subcutaneously [4].
3.1.1. EU guideline for non-clinical evaluation of SBMPs containing
recombinant somatropin as active substance
As laid down in the respective EU guideline [4], the following
non-clinical data should usually be provided for marketing
authorisation approval application:
Pharmacodynamic studies: (i) Data from a number of compara-
tive in vitro bioassays (e.g. receptor-binding studies, cell prolifera-
tion assays). (ii) An appropriate in vivo rodent model (e.g. the
weight-gain assay and/or the tibial growth assay in immature
hypophysectomized rats) should be used to quantitatively compare
the pharmacodynamic activity of the SBMP and the RBMP.
Toxicological studies: Data from at least one repeat dose toxicity
study (RDTS) in a relevant species (e.g. rat) should be provided [17].
Study duration should be at least 4 weeks and the study should
include appropriate toxicokinetic measurements [18], comprising
also a determination of anti-somatropin antibody formation [16]. In
addition, data on local tolerance [19] in at least one species should
be provided, if feasible, obtained from the described RDTS.3.1.2. Non-clinical data provided for marketing authorisation of
SBMPs approved in the EU and containing recombinant somatropin
as an active substance
Omnitrope [20]: Omnitrope is produced in E. coli. As RBMP
Genotropin was used. Pharmacodynamic studies: In accordance
with the provisions of the guideline, pharmacodynamic activity
was evaluated in vitro in cell-based assays and in in vivo rodent
growth assays.
Toxicological studies: Data about a RDTS in rats and a local
tolerance study in rabbits were provided. However, both studies
were performed in a non-comparative manner, the duration of the
RDTS was only 14 days and anti-somatropin antibody formation
was not determined.
Valtropin [21]: Valtropin is produced in Saccharomyces cer-
evisiae. As RBMP Humatrope was used.
Pharmacodynamic studies: In accordance with the provisions of
the GL, pharmacodynamic activity was evaluated in in vivo rodent
growth assays.
Toxicological studies: Data about RDTSs in rats and mice (in both
species of 4 weeks and of 3 months duration) were provided, and
the local tolerance was evaluated in the RDTSs. All toxicity studies
were performed in a non-comparative manner and anti-
somatropin antibody formation was not determined.3.2. Granulocyte-colony stimulating factor
Human G-CSF consists of a single polypeptide chain of 174
amino acids with O-glycosylation at one threonine residue.
Recombinant G-CSFs produced in E.coli (ﬁlgrastim) and in Chinese
hamster ovary (CHO) cells (lenograstim) are in clinical use.
Compared to the human and the CHO-derived G-CSF, the E. coli
protein has an additional amino-terminal methionine and no
glycosylation. The recombinant G-CSF protein contains one free
cysteinyl residue and two disulphide bonds.
Effects of G-CSF on the target cells are mediated through its
trans-membrane receptor that forms homo-oligomeric complexes
upon ligand binding. Several isoforms of the G-CSF receptor arising
from alternative RNA splicing, leading to differences in the intra-
cytoplasmic sequences, have been isolated. One soluble isoform is
known. However, the extracellular ligand-binding domains of the
known isoforms are identical. Consequently, it is considered that
the effects of recombinant G-CSF are mediated via a single afﬁnity
class of receptors.
Recombinant G-CSF can be used for several purposes such as: (i)
reduction in the duration of neutropenia after cancer chemo-
therapy or myeloablative therapy followed by bone marrow
transplantation; (ii) mobilisation of peripheral blood progenitor
cells; (iii) for treatment of severe congenital, cyclic, or idiopathic
neutropenia; (iv) treatment of persistent neutropenia in patients
with advanced human immunodeﬁciency virus (HIV) infection. The
posology varies between these conditions. G-CSF can principally be
administered intravenously or subcutaneously [7].
3.2.1. EU guideline for non-clinical evaluation of SBMPs containing
recombinant G-CSF as active substance
As laid down in the respective guideline [7], the following non-
clinical data should usually be provided for marketing author-
isation application:
Pharmacodynamic studies: (i) Data from a number of compara-
tive in vitro bioassays (e.g. receptor-binding studies, cell prolifera-
tion assays) should be provided. (ii) In vivo rodent models,
neutropenic and non-neutropenic, should be used to compare the
pharmacodynamic effects of the SBMP and the RBMP.
Toxicological studies: As described for somatropin.
H.-K. Heim / Biologicals 39 (2011) 284e288 2873.2.2. Non-clinical data provided for marketing authorisation of
SBMPs approved in the EU and containing recombinant G-CSF
as active substance
Filgrastim Hexal [22], Zarzio [23]: These G-CSFs (identical
products marketed under two different trade names) are produced
in E. coli. As RBMP Nupogen (ﬁlgrastim) was used. Pharmacody-
namic studies: In accordance with the provisions of the guideline,
pharmacodynamic activity was evaluated in vitro in cell-based
bioassays and in receptor-binding studies and in vivo in neu-
tropenic and non-neutropenic rodent models.
Toxicological studies: Data on a comparative 4-week RDTS in rats
with a 6-week recovery period, including toxicokinetic measure-
ments and determination of anti-G-CSF antibody formation, were
provided. In addition, a comparative tolerance study was per-
formed in rabbits.
Biograstim [24], Filgrastim ratiopharm [25], Ratiograstim [26],
Tevagrastim [27]: These G-CSFs (identical products marketed under
four different trade names) were produced in E. coli. As RBMP
Nupogen (ﬁlgrastim) was used.
Pharmacodynamic studies: In accordance with the provisions of
the guideline, pharmacodynamic activity was evaluated in vitro in
cell-based bioassays and in receptor-binding studies and in vivo in
comparative studies in neutropenic mice and in non-neutropenic
rats. In addition, data from a non-comparative study in cyn-
omolgus monkeys were provided. Toxicological studies: Data about
non-comparative 26-week RDTSs in rats and in cynomolgus
monkeys were provided. Toxicokinetic measurements were only
reported for the latter study and anti-G-CSF antibody formation
was not evaluated. Local tolerance was studied in two studies in
rabbits, one with and one without a comparator.
Other studies: Separate pharmacokinetic studies in rats and
monkeys were provided. Anti-G-CSF antibody formation was
evaluated in a comparative antigenicity study in rats (study design:
2 weeks of treatment, followed by a 2-week treatment-free period,
followed by another 2 weeks of treatment; determination of
percentage of AB positive animals and of AB concentration at day
28 and, after another 2-week treatment-free period, at day 56).
Furthermore, secondary pharmacology, safety pharmacology and
single dose toxicity were evaluated in non-comparative studies.
Nivestim [28]: This G-CSF is produced in E. coli. As RBMP Nup-
ogen (ﬁlgrastim) was used. Pharmacodynamic studies: In accor-
dancewith the provisions of the GL, pharmacodynamic activity was
evaluated in vitro in cell-based bioassays and in receptor-binding
studies and in vivo in neutropenic and non-neutropenic rodent
models.
Toxicological studies: Data about a comparative 4-week RDTS in
rats with a 2-week recovery period, including toxicokinetic
measurements and determination of anti-G-CSF antibody forma-
tion, were provided. In addition, a comparative tolerance study in
rabbits was performed.
3.3. Erythropoietin
Human erythropoietin is a 165 amino acid glycoprotein mainly
produced in the kidneys and is involved in stimulation of red blood
cell production. Erythropoietin for clinical use is currently
produced by recombinant DNA technology using mammalian cells
as an expression system and termed epoetin. All epoetins in clinical
use have a similar amino acid sequence as endogenous erythro-
poietin but differ in the glycosylation pattern. Glycosylation inﬂu-
ences pharmacokinetics and may affect efﬁcacy and safety
including immunogenicity.
Epoetin-containing medicinal products are currently indicated
for several conditions such as anaemia in patients with chronic
renal failure, chemotherapy-induced anaemia in cancer patients,and for increasing the yield of autologous blood from patients in
a pre-donation programme. The mechanism of action of epoetin is
considered to be the same in all currently approved indications but
the dosages required to achieve the desired response may vary
considerably and are highest in the oncology indications. Epoetin
can principally be administered intravenously or subcutaneously
[5,6].
3.3.1. EU guideline for non-clinical evaluation of SBMPs containing
erythropoietin as active substance
As laid down in the respective EU guideline [5,6], the following
non-clinical data should usually be provided for marketing
authorisation application:
Pharmacodynamic studies: (i) Data from a number of compara-
tive in vitro bioassays (e.g. receptor-binding studies, cell prolifera-
tion assays) should be provided. (ii) The erythrogenic effects of the
SBMP and the RBMP should be quantitatively compared in vivo in
an appropriate animal assay. Information on the erythrogenic
activity may be obtained from the requested RDTS or from
a speciﬁcally designed assay (e.g. the European Pharmacopoeia
normocythaemic mouse assay).
Toxicological studies: As described for somatropin.
3.3.2. Non-clinical data provided for marketing authorisation of
SBMPs approved in the EU and containing recombinant
erythropoietin as active substance
Abseamed [29], Binocrit [30], Epoietin alfa Hexal [31]: These
erythropoietins (identical products marketed under three different
trade names) are produced in CHO cells. As RBMP Erypo/Eprex
(epoetin alfa) was used.
Pharmacodynamic studies: In accordance with the provisions of
the guideline, pharmacodynamic activity was evaluated in vitro in
cell-based assays and in vivo in an erythrogenic mouse assay. In
addition, erythrogenic activity was evaluated in vivo in a 5-week
study in dogs.
Toxicological studies: Data about a comparative RDTS in dogs
(13 weeks duration plus 5 weeks recovery period) were provided,
including toxicokinetic and anti-erythropoietin antibody
measurements. Local tolerance was evaluated in 2 rabbit studies
(without comparator) and in the RDTS.
Other studies: An additional pharmacokinetic study in dogs was
performed.
Retacrit[32], Silapo[33]: These erythropoietins (identical prod-
ucts marketed under two different trade names) are produced in
CHO cells. As RBMP Erypo/Eprex (epoetin alfa) was used.
Pharmacodynamic studies: In accordance with the provisions of
the guideline, pharmacodynamic activity was evaluated in vitro in
cell-based assays and in vivo in an erythrogenic mouse assay.
Toxicological studies: Data about comparative RDTSs in rats (13
weeks duration) and dogs (13 weeks duration plus 5 weeks
recovery period) were provided, including toxicokinetic and anti-
erythropoietin antibody measurements. Local tolerance was eval-
uated in a rabbit study (without comparator) and in the RDTSs.4. Conclusions concerning the non-clinical study program
of SBMPs already licensed in the EU and future perspectives
for licensing of SBMPs in the EU
In the EU, a regulatory framework has been established which
deﬁnes general conditions (as laid down in the so-called overarching
guidelines [1,3]) for approval of SBMPs and provides product-class
speciﬁc recommendations to choose relevant species and adequate
test conditions for non-clinical evaluation of speciﬁc SBMPs con-
taining as active substances for example recombinant somatropin,
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weight heparins.
During the last years, a number of SBMP containing as active
substance recombinant somatropin, G-CSF or erythropoietin have
been successfully licensed in the EC.
Obviously, for many of these products, the non-clinical evalua-
tion was performed before the respective product-class speciﬁc
guidelines came into force. It is therefore comprehensible that
deviations from the non-clinical study program currently recom-
mended by the respective EU biosimilar guidelines do exist to some
extent for most of the currently licensed products.
However, it can be seen that common basic concepts were
applied for non-clinical evaluation of all SBMPs currently
approved in the EU. In fact, the non-clinical evaluation of the
licensed SBMPs containing recombinant somatropin, G-CSF or
erythropoietin as an active substance comprised, besides in vitro
pharmacodynamic studies on biological activity, in vivo studies
on pharmacodynamic activity and on toxicity. Toxicity was eval-
uated in at least one RDTS and data on local tolerance were
provided, the latter based either on a separate study or on data
obtained from the RDTS.
For some of the currently approved SBMPs, the extent of the
non-clinical study program clearly exceeds the requests currently
laid down in the respective EU guidelines. On the other hand, not in
all cases the studies were performed in a comparative manner,
while a comparative study design constitutes a basic feature of the
‘comparability exercise’ requested by the current EU guidelines.
It is expected that concerning non-clinical evaluation, future
marketing authorisation applications for SBMPs in the EUwill adhere
closely to the existing EU regulatory guidelines for SBMPs, since
pharmaceutical companies now have the opportunity to build up
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